Xcovery Holdings

Oncology

Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.

News

Ipsen has agreed to buy cancer biotech Kartos Therapeutics for $450m upfront, adding a late-stage drug in the challenging MDM2 inhibitor class.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.